Cannabis Shows Promise for Autoimmune Diseases, but Evidence Remains Thin | Research

The takeaway

A review found encouraging perspectives on cannabis for autoimmune and rheumatic conditions, but noted the evidence remains insufficient and needs validation through rigorous clinical trials.

Rheumatology patients and providers, autoimmune disease researchers, medical cannabis advocates

Cannabis shows promise for autoimmune conditions but evidence remains insufficient for clinical use

What the researchers found

Cannabis-based treatments show potential benefits across various autoimmune and rheumatic conditions, but in many cases the supporting evidence is insufficient. Social and legal barriers have hindered the rigorous clinical trials needed to validate these findings.

Why it matters

Autoimmune diseases affect millions and current treatments often have significant side effects. If cannabis-based therapies prove effective, they could offer a complementary or alternative approach.

The numbers in context

Review covers multiple autoimmune and rheumatic conditions; specific outcome data from individual studies cited in full text.

How the study worked

Review of updated data on cannabis-based treatments for autoimmune and rheumatic conditions including their potential therapeutic roles.

What this study cannot tell us

Evidence base is largely preclinical or from small studies. Regulatory and legal barriers have prevented large-scale clinical trials. Optimal formulations, doses, and cannabinoid combinations unknown.

How to read the evidence

Review identifies encouraging trends but explicitly acknowledges the evidence is insufficient for clinical recommendations.

When this study was published

2025 review capturing current state of cannabis-autoimmune research.

The bigger picture

The endocannabinoid system plays a documented role in immune regulation, providing a biological rationale for cannabis in autoimmune conditions. However, the gap between biological plausibility and clinical proof remains wide.

Questions still open

Which autoimmune conditions are most likely to benefit from cannabis treatment? Can cannabis reduce the need for conventional immunosuppressants? What role does the route of administration play?

Common questions

Can cannabis help with autoimmune diseases?

There are encouraging signs from preclinical research and small studies, but this review emphasizes that the evidence is not yet strong enough to make clinical recommendations. Larger trials are needed.

Why is there so little evidence on cannabis for autoimmune conditions?

Social stigma and legal barriers in many countries have made it difficult to conduct the rigorous clinical trials needed. Cannabis's regulatory status has historically impeded research funding and access.

Read the original research

Exploring therapeutic potential of Cannabis based therapy in autoimmune and rheumatic disorders.

Autoimmunity reviews, 24(12), 103925

View on PubMed ↗Publisher’s paper ↗

Citation

Michaeli, Inbar; Lassman, Simon; Halpert, Gilad; Jacob, Giris; Amital, Howard. (2025). Exploring therapeutic potential of Cannabis based therapy in autoimmune and rheumatic disorders.. Autoimmunity reviews, 24(12), 103925. https://doi.org/10.1016/j.autrev.2025.103925